

BACKGROUND

Pharmacokinetics (PK) of drugs that target B-cells is often described by a model with time-dependent clearance that is influenced by disease characteristics [1, 2]. Dependence of clearance on expression, accessibility, and amount of target is indicative of target-mediated elimination, similarly to the example provided in [3], where drug elimination was described as a combination of linear clearance and elimination via free receptors on neutrophils.

OBJECTIVES

To provide a possible mechanistic explanation of the observed time-dependency of PK and dependency of time-dependent clearance on disease characteristics.

METHODS/RESULTS

It was assumed that PK of the drug is described by a two-compartment model with parallel linear and target-mediated elimination with (a) **irreversible binding**; (b) **receptor recycling** (resulting in constant number of receptors on each cell), and (c) **and limited access of the drug to the target cells** (leading to relatively slow effective binding rate).

Then TMDD equations can be written as:

$$\frac{dA_1}{dt} = -\left(\frac{CL_{ns} + Q}{V_c}\right)A_1 + \frac{Q}{V_p}A_2 - k_{int}A_1R; \quad A_1(0) = D_{IV};$$

$$\frac{dA_2}{dt} = \frac{CL_{ns}}{V_c}A_1 - \frac{Q}{V_p}A_2; \quad A_2(0) = 0; \quad C = \frac{A_1}{V_c};$$


$$\frac{dR}{dt} = k_{syn} - k_{deg}R - k_{kill}R \frac{C}{IC_{50} + C}; \quad R(0) = k_{syn} / k_{deg}.$$

Here target-mediated elimination $k_{int} \cdot A_1 \cdot R$ is proportional to the drug amount A_1 , the target cell concentration R , and internalization rate k_{int} that may depend on drug-target binding rate k_{on} , density and turnover of target receptors. Target cells are in equilibrium prior to drug administration; kill rate of target cells can be described by Emax function of drug concentrations $k_{kill} \cdot R \cdot C / (IC_{50} + C)$.

If IC_{50} is significantly lower than trough concentration C_{trough} , then one can derive equation

$$dR/dt = k_{syn} - (k_{deg} + k_{kill})R; \quad t > 0; \quad R(0) = R_0 = k_{syn} / k_{deg}, \quad \text{that has a solution}$$

$$R = R_0 \left(\frac{k_{deg}}{k_{deg} + k_{kill}} + \frac{k_{kill}}{k_{deg} + k_{kill}} e^{-(k_{deg} + k_{kill}) \cdot t} \right); \quad t > 0.$$



METHODS/RESULTS (continuation)

Substituting expressions for the concentration of target cells in the equation for A_1 , one can arrive at the equation

$$\frac{dA_1}{dt} = -\left(\frac{CL_{ns} + Q}{V_c}\right)A_1 + \frac{Q}{V_p}A_2 - \frac{CL_R}{V_c}A_1; \quad CL_R = k_{int}R_0 \left(\frac{k_{deg}}{k_{deg} + k_{kill}} + \frac{k_{kill}}{k_{deg} + k_{kill}} e^{-(k_{deg} + k_{kill}) \cdot t} \right) \cdot V_c$$

The expression for clearance in this equation can be rewritten as

$$CL(t) = CL_{SS} + CL_T e^{-k \cdot t}, \quad \text{where} \quad k = k_{deg} + k_{kill};$$

$$CL_{SS} = CL_{ns} + k_{int}R_0 \cdot V_c \frac{k_{deg}}{k_{deg} + k_{kill}} = CL_{ns} + \frac{k_{int}k_{syn}}{k_{deg} + k_{kill}} V_c;$$

$$CL_T = k_{int}R_0 \cdot V_c \frac{k_{kill}}{k_{deg} + k_{kill}} = \frac{k_{int}k_{syn}k_{kill}}{k_{deg} + k_{kill}} V_c;$$

Thus, CL_{SS} and CL_T may be higher at higher baseline target cell concentration R_0 , higher synthesis rate k_{syn} , and higher receptor density (that would lead to increase of k_{int}) and may be lower with concomitant chemotherapy (that decreases k_{syn}). In addition, concomitant chemotherapy may increase kill rate k_{kill} (synergy), leading to decrease of CL_{SS} , but increase of CL_T and k . For subjects with low kill rate (non-responders), CL_{SS} would be higher leading to lower exposure. Thus, the often observed PK-PD relationship where lower exposure leads to lower probability of response could be a consequence of being non-responder rather than the cause of non-response.

CONCLUSIONS

Under reasonable assumptions, equations of the linear system with time-dependent clearance can be derived from target-mediated drug disposition equations. This explains the PK structural model and covariate dependencies that are typical for drugs that target B-cells.

REFERENCES

- [1] Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N, Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3:e144. doi: 10.1038/psp.2014.42..
- [2] Li JI, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, Mangat R, Joshi A, Visich J., Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia, J Clin Pharmacol. 2012 Dec;52(12):1918-26. doi: 10.1177/0091270011430506. Epub 2012 Jan 10.
- [3] Jonsson EN, Macintyre F, James I, Krams M, Marshall S., Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition., Pharm Res. 2005 Aug;22(8):1236-46. Epub 2005 Aug 3.

ACKNOWLEDGEMENTS

We are grateful to Dr. Donald Mager for stimulating discussions.

